Crossing A Frontier In Cardiac Fibrosis: A Single-cell Multi-omics Approach To Understanding Fibroblast Agency In Models Of Heart Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,199,254.00
Summary
Cardiovascular disease is the most serious cause of mortality and morbidity in society, with one Australian dying every 13 mins. Our focus is on cardiac fibroblasts - changeable cells that regulate the mechanical integrity of the heart, and which are key therapeutic targets in heart disease. Single cell methods have revolutionised the study of complex tissues. Here we will apply molecular assays to thousands of single heart cells to build a new conceptual framework for fighting heart disease.
A New Mechanism Of Tissue Fibrosis - A Small Peptide Regulator Of The TGF-beta1/Smad Pathway
Funder
National Health and Medical Research Council
Funding Amount
$768,757.00
Summary
Progressive scarring, or fibrosis, of organs leads to their loss of function. Fibrotic diseases are devastating to both the individual and our community and we lack effective therapies. We have identified a small protein, named SPRF, which represents a new mechanism in tissue fibrosis. These studies will examine the role of the SRPF protein in models of kidney, heart and lung fibrosis and its underlying mechanism of action. We will also test a therapy based on inhibiting SPRF function.
Targeting The Crosstalk Between Metabolism And Epigenetics To Treat Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,032,259.00
Summary
Virtually all liver disease related morbidity and mortality is a consequence of fibrosis that culminates in liver failure or liver cancer. Since anti-fibrotic drugs are not available, new approaches to drug development are required. We have discovered a novel strategy for such drug development by modifying the expression of a specific gene (RARRES1) in a highly targeted manner and thereby interrupting the energy production that is needed by cells to drive fibrosis.